The Xywav Drug and Dealing with Daytime Sleepiness

 The Director of medical toxicology at Rutgers New Jersey Medical School, Dr. Lewis S. Nelson, says about 40,000 people are diagnosed with idiopathic insomnia in the United States. Of every 5 Americans, 1 sees a doctor with a complaint of daytime sleepiness.


Insomnia, idiopathic insomnia, tired, sleepiness, xywav, FDA


On July 21, 2021, the kood and Drug Administration of the United states approved the drug Xywav (calcium, magnesium, potassium, and sodium oxybate) to treat daytime sleepiness called idiopathic insomnia. The drug was granted "orphan drug" status and is approved to treat the rare condition affecting less than 200,000 people in the United States. The Dublin-based Jazz Pharmaceuticals got the approval for nanufacturing and marketing the drug in the United States. While feeling tired throughout the day is common among people, some individuals have excessive daytime sleepiness and face significant challenges in school, work, and social relationships. Excessive daytime sleepiness is known as hypersomnia, and idiopathic hypersomnia is one form with no known cause. The Director of medical toxicology at Rutgers New Jersey Medical School, Dr. Lewis S. Nelson, says about 40,000 people are diagnosed with idiopathic insomnia in the United States. Of every 5 Americans, 1 sees a doctor with a complaint of daytime sleepiness.

Comments

Popular posts from this blog

Everything you need to know about subspecialties of Radiology

Top Cardiology Conferences From eMedEvents to Attend in 2023